U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention RSV Lower Respiratory Tract Disease in Infants
On Jun. 9, 2025, Merck announced the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA™ (clesrovimab-cfor) for…
Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening U.S. presence
On May 22, 2025, Sanofi announces the formal opening of the company’s new flagship U.S. offices, unveiling a…
Disease | FDA | Neurology | Pharmaceutical | Therapeutics
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for Acute Treatment of Migraine
On May 15, 2025, Amneal Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved Brekiya®…
Sanofi to invest $20 billion in U.S. through 2030
On Mar. 14, 2025, Sanofi announced that it plans to invest at least $20 billion in the United…
Innovation Pharmaceuticals reported Brilacidin inhibited Omicron, Delta, Gamma and Alpha SARS-CoV-2 variants
On Jun. 23, 2022, Innovation Pharmaceuticals reported that Brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity,…
Tonix Pharm announced results of retrospective observational database study in over 50,000 long COVID patients
On Apr. 20, 2022, Tonix Pharmaceuticals announced the results of a retrospective observational database study in over 50,000…
Tonix Pharma announced exclusive collaboration with Kansas State University to develop LNP-Free mRNA vaccines
On Jan. 4, 2022, Tonix Pharmaceuticals announced an exclusive option agreement and research collaboration with Kansas State University…
Tonix Pharmaceuticals announced publication of paper on antiviral SARS-CoV-2 inhibitor, TNX-3500, in JCI Insight
On Nov. 22, 2021, Tonix Pharmaceuticals announced the publication of ‘Sangivamycin is highly effective against SARS-CoV-2 in vitro…
Tonix Pharmaceuticals expanded research collaboration to develop precision medicine techniques for COVID-19 vaccines and therapeutics
On Sept. 23, 2021, Tonix Pharmaceuticals announced it had expanded its research collaboration with Columbia University. The research…
Tonix Pharmaceuticals announced program to develop TNX-102 SL for treatment of long COVID syndrome
On Jun. 21, 2021, Tonix Pharmaceuticals announced that it planned to develop TNX-102 SL (cyclobenzaprine HCl sublingual tablets)…
Sanofi and GSK initiated global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
On May 27, 2021, Sanofi and GlaxoSmithKline started enrolment in their Phase 3 clinical study to assess the…
Biotechnology | COVID-19 | Disease | Infectious Disease | Oncology | Rare Disease | Therapeutics | Vaccine
Moderna announced agreement with Sanofi for manufacturing of Moderna COVID-19 Vaccine in the U.S.
On Apr. 26, 2021, Moderna announced that it had entered into an agreement with Sanofi for fill/finish sterile…
Tonix Pharma entered worldwide licensing agreement to develop antiviral SARS-CoV-2 inhibitor for treatment of COVID-19
On Apr. 19, 2021, Tonix Pharmaceuticals and OyaGen announced an exclusive worldwide licensing agreement for an antiviral inhibitor…
Tonix Pharma reported positive COVID-19 vaccine efficacy results in non-human primates vaccinated with TNX-1800
On Mar. 17, 2021, Tonix Pharma announced preliminary results following vaccination of non-human primates with TNX-1800 (modified horsepox…
Tonix Pharmaceuticals to develop COVID-19 skin test to measure SARS-CoV-2 exposure and T cell immunity
On Feb. 8, 2021, Tonix Pharmaceuticals announced it had received the written response from the U.S. Food and…
Cue’s Molecular, point-of-care COVID-19 tests deployed to five states in HHS and DOD pilot program
On Nov. 19, 2020, Cue Health announced that, as of November 9, the U.S. Department of Health and…
Tonix Pharmaceuticals reported positive immune response results from COVID-19 Vaccine candidate
On Nov. 16, 2020, Tonix Pharmaceuticals announced preliminary results following vaccination of non-human primates with TNX-1800 (modified horsepox…
Tonix Pharmaceuticals enrolled first participant in PRECISION Study for COVID-19 vaccines and therapeutics
On Oct. 15, 2020, Tonix Pharmaceuticals announced that the first participant was enrolled in the observational PRECISION study…
Tonix Pharma completed the purchase of a facility to house advanced development center for vaccine programs
On Sept. 28, 2020, Tonix Pharmaceuticals announced that it had completed the purchase a 40,000 square foot facility…
Tonix Pharma enrolled first patient in COV-LOGIC study to assess antibody and T cell responses to SARS-CoV-2
On Sept. 15, 2020,Tonix Pharmaceuticals announced that the first patient was enrolled in the observational COV-LOGIC study (TNX-C001),…
Tonix Pharma announced research collaboration to develop precision medicine techniques for COVID-19 vaccines and therapeutics
On Jul. 16, 2020, Tonix Pharmaceuticals announced it had entered into a research collaboration and option agreement with…
Tonix Pharma announced plans for Massachusetts R&D facility to accelerate clinical development of vaccines and protein-based therapeutics
On Jul. 7, 2020, Tonix Pharmaceuticals announced its intent to purchase an approximately 40,000 square foot facility in…
University of Alberta researcher to test whether COVID-19 antibodies provide long-term immunity
On Jun. 25, 2020, the University of Alberta (U of A) announced a study that will analyze thousands…
Tonix Pharma and Southern Research announced expansion of COVID-19 vaccine collaboration
On Jun. 18, 2020, Tonix Pharmaceuticals announced an expansion of its strategic collaboration with Southern Research to include…
Tonix Pharma announced FUJIFILM Diosynth Biotechnologies to be Manufacturing partner for COVID-19 vaccine candidate TNX-1800
On Jun. 1, 2020, Tonix Pharmaceuticals announced an agreement whereby FUJIFILM Diosynth Biotechnologies will provide contract manufacturing and…
Amneal Pharmaceuticals donated hydroxychloroquine sulfate to state of Texas
On Mar. 26, 2020, Amneal Pharma announced it had donated 1,000,000 hydroxychloroquine sulfate tablets to the Texas State…
Seqirus’ Received Health Canada approval of first cell-based seasonal influenza vaccine
On Dec. 11, 2019, Seqirus announced that its cell-based quadrivalent influenza vaccine (QIVc) had received approval from Health…
Teva Pharmaceuticals announced North America headquarters moved to New Jersey
On Jul. 6, 2018, Teva Pharmaceuticals announced it would move its U.S. headquarters to Parsippany-Troy Hills, New Jersey…
The Lombardi Comprehensive Cancer Center became the 16th National Cancer Institute-designated Comprehensive Cancer Center
In 2018, the Lombardi Comprehensive Cancer Center became the 16th National Cancer Institute-designated Comprehensive Cancer Center funded with…
Bristol-Myers Squibb announced closure of Seattle’s ZymoGenetics operation
On Dec. 13, 2016, Bristol-Myers Squibb announced that it would not renew its lease at the Lake Union…